18F-Sodium fluoride positron emission tomography: History, technical feasibility, mechanism of action, normal bio-distribution, and diagnostic performance in bone metastasis detection compared to other imaging modalities.
暂无分享,去创建一个
[1] H. Zacho,et al. No Added Value of 18F-Sodium Fluoride PET/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy , 2019, The Journal of Nuclear Medicine.
[2] Yue Chen,et al. Comparison of 18F-NaF PET/CT and 18F-FDG PET/CT for Detection of Skull-Base Invasion and Osseous Metastases in Nasopharyngeal Carcinoma , 2018, Contrast media & molecular imaging.
[3] Nagabhushan Seshadri,et al. Skeletal Metastases and Benign Mimics on NaF PET/CT: A Pictorial Review. , 2018, AJR. American journal of roentgenology.
[4] F. Mottaghy,et al. Correction to: 18F-NaF PET/CT: EANM procedure guidelines for bone imaging , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[5] B. Chatterton,et al. 18-Fluoride labeled sodium fluoride positron emission tomography with computer tomography: the impact of pretreatment staging in intermediate- and high-risk prostate cancer , 2017, Prostate international.
[6] Giuseppe Esposito,et al. Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease , 2017, The Journal of Nuclear Medicine.
[7] Lucy Hanna,et al. Intended Versus Inferred Treatment After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry , 2017, The Journal of Nuclear Medicine.
[8] N. Gupta,et al. Usefulness of Radium-223 in Patients with Bone Metastases , 2017, Proceedings.
[9] P. Hogg,et al. The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer , 2016, The Journal of Nuclear Medicine Technology.
[10] P. Choyke,et al. Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer , 2016, The Journal of Nuclear Medicine.
[11] Valentina Taviani,et al. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer , 2015, The Journal of Nuclear Medicine.
[12] G. Aras,et al. The role of 18F–NaF PET/CT in metastatic bone disease , 2015, Journal of bone oncology.
[13] F. Mottaghy,et al. 18F-NaF PET/CT: EANM procedure guidelines for bone imaging , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[14] Lucy Hanna,et al. 18F-Fluoride PET Used for Treatment Monitoring of Systemic Cancer Therapy: Results from the National Oncologic PET Registry , 2015, The Journal of Nuclear Medicine.
[15] Quan-Yong Luo,et al. Performance of 18F-Fluoride PET or PET/CT for the Detection of Bone Metastases: A Meta-analysis , 2015, Clinical nuclear medicine.
[16] R. Jeraj,et al. Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients. , 2015, American journal of nuclear medicine and molecular imaging.
[17] M. H. Poulsen,et al. Spine metastases in prostate cancer: comparison of technetium‐99m‐MDP whole‐body bone scintigraphy, [18F]choline positron emission tomography(PET)/computed tomography (CT) and [18F]NaF PET/CT , 2014, BJU international.
[18] David S W Djang,et al. Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice. , 2014, Radiographics : a review publication of the Radiological Society of North America, Inc.
[19] M. Perry,et al. Molecular imaging in oncology: (18)F-sodium fluoride PET imaging of osseous metastatic disease. , 2014, AJR. American journal of roentgenology.
[20] R. Coleman,et al. Impact of 18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry , 2014, The Journal of Nuclear Medicine.
[21] R. Coleman,et al. Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry , 2014, The Journal of Nuclear Medicine.
[22] G. Segall. PET/CT with Sodium 18F-Fluoride for Management of Patients with Prostate Cancer , 2014, The Journal of Nuclear Medicine.
[23] D. Hose,et al. PET/CT studies of multiple myeloma using 18 F-FDG and 18 F-NaF: comparison of distribution patterns and tracers’ pharmacokinetics , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[24] F. M. van der Zant,et al. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer , 2013, Nuclear medicine communications.
[25] D. Chakraborty,et al. Comparison of 18F Fluoride PET/CT and 99mTc-MDP Bone Scan in the Detection of Skeletal Metastases in Urinary Bladder Carcinoma , 2013, Clinical nuclear medicine.
[26] R. Herfkens,et al. Pilot Prospective Evaluation of 99mTc-MDP Scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and Whole-Body MRI for Detection of Skeletal Metastases , 2013, Clinical nuclear medicine.
[27] U. Tateishi,et al. Assessment of atherosclerosis in oncologic patients using 18F-fluoride PET/CT , 2013, Annals of Nuclear Medicine.
[28] Lalit Kumar,et al. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan , 2013, Japanese Journal of Radiology.
[29] G. Cook. Combined 18F-Fluoride and 18F-FDG PET/CT Scanning for Evaluation of Malignancy: Results of an International Multicenter Trial , 2013, The Journal of Nuclear Medicine.
[30] T. Ohlsson,et al. Combined 18F‐fluorocholine and 18F‐fluoride positron emission tomography/computed tomography imaging for staging of high‐risk prostate cancer , 2012, BJU international.
[31] T. Yen,et al. Utility of 18F-Fluoride PET/CT and 18F-FDG PET/CT in the Detection of Bony Metastases in Heightened-Risk Head and Neck Cancer Patients , 2012, The Journal of Nuclear Medicine.
[32] C. Ramos,et al. 18F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[33] S. Groshen,et al. Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer , 2012, Clinical nuclear medicine.
[34] E. Mittra,et al. Prospective Evaluation of 99mTc MDP Scintigraphy, 18F NaF PET/CT, and 18F FDG PET/CT for Detection of Skeletal Metastases , 2012, Molecular Imaging and Biology.
[35] O. Cussenot,et al. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[36] Sue Chua,et al. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin) , 2011, EJNMMI research.
[37] Nagichettiar Satyamurthy,et al. Molecular Mechanisms of Bone 18F-NaF Deposition , 2010, The Journal of Nuclear Medicine.
[38] Michael G. Stabin,et al. SNM Practice Guideline for Sodium 18F-Fluoride PET/CT Bone Scans 1.0* , 2010, The Journal of Nuclear Medicine.
[39] U. Tateishi,et al. A meta-analysis of 18F-Fluoride positron emission tomography for assessment of metastatic bone tumor , 2010, Annals of nuclear medicine.
[40] Yen-Wen Wu,et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients , 2010, Nuclear medicine communications.
[41] U. Tateishi,et al. 18F-fluoride uptake in bone metastasis: morphologic and metabolic analysis on integrated PET/CT , 2010, Annals of nuclear medicine.
[42] Christian Schumann,et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[43] E. Mittra,et al. Novel Strategy for a Cocktail 18F-Fluoride and 18F-FDG PET/CT Scan for Evaluation of Malignancy: Results of the Pilot-Phase Study , 2009, Journal of Nuclear Medicine.
[44] P. Waldenberger,et al. Assessment of malignant and benign bone lesions by static F-18 Fluoride PET-CT: Additional value of SUV! , 2008 .
[45] S Ted Treves,et al. Skeletal PET with 18F-Fluoride: Applying New Technology to an Old Tracer* , 2007, Journal of Nuclear Medicine.
[46] U. Metser,et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[47] Eyal Mishani,et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[48] H. Schirrmeister,et al. F‐18 NaF PET for Detection of Bone Metastases in Lung Cancer: Accuracy, Cost‐Effectiveness, and Impact on Patient Management , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[49] H. Schirrmeister,et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[50] G. Blake,et al. Quantitative studies of bone using 18F-fluoride and 99mTc-methylene diphosphonate: evaluation of renal and whole-blood kinetics , 2001, Nuclear medicine communications.
[51] H. Schirrmeister,et al. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. , 2001, Thyroid : official journal of the American Thyroid Association.
[52] I. Fogelman,et al. Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[53] J Kotzerke,et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[54] H. Schirrmeister,et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] J. Bergh,et al. Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT , 1998, Skeletal Radiology.
[56] P. Kantoff,et al. (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. , 2015, American journal of nuclear medicine and molecular imaging.